← All trials
NCT06077864
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 17, 2023
- Primary completion
- Mar 12, 2026
- Completion date
- Apr 2, 2026
- First posted
- Oct 11, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 4935
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.